Cannabis Report
Home > Boards > US OTC > Miscellaneous >

Therapeutic Solutions International, Inc. (TSOI)

Add TSOI Price Alert      Hide Sticky   Hide Intro
Moderator: gotinearly, Wall $treet Kid, subslover, centsability4me, emptypants
Search This Board: 
Last Post: 7/15/2018 11:17:51 PM - Followers: 130 - Board type: Free - Posts Today: 0

Therapeutic Solutions International, Inc.

is a public company  focused on immune
modulation for the treatment of several specific diseases

(TSOI Products : 6- Biologics in RED, 4- Anti-oxidants/Nutraceuticals in PURPLE)

NEWS : 7/9/18

Therapeutic Solutions International, Inc., Appoints Juergen Winkler, MD, ABIHM to Scientific Advisory Board

Pioneer of Functional Medicine Teams Up with Clinical Stage Biotechnology Company in Commercialization of Non-Toxic Immunotherapy

Oceanside, CA -- July 9, 2018 -- InvestorsHub NewsWire -- Therapeutics Solutions International, Inc., (OTC Markets: TSOI) announced today that Juergen Winkler, M.D., has been appointed to the Company's Scientific Advisory Board.

Dr. Winkler is presently practicing at Quantum Functional Medicine in Carlsbad, CA, which he founded in 2012. Dr. Winkler has been a featured speaker for: the NSCC Women's Health Seminar, Annual IPT/IPTLD Integrative Cancer Care Conference (Multiple years), Health Freedom Expo 2011 & 2012, the Japanese Society of Oxidative Medicine in Osaka Japan, ACOSPM 2010 & 2011 conferences, NSCC Health and Wellness Series 2013, and various other events. He is the physician author of Chapter 5 in "Defeat Cancer", a book describing leading physicians on the forefront of the battle with Cancer.

"We are really excited to have Dr. Winkler join our team, working collaboratively with him in the background he has helped us to refine our latest product NanoStilbene, a nanoparticle formulation of pterostilbene, clinically shown to more effectively increase blood levels of the molecule as compared to conventional powder formulations", said Timothy Dixon, President and CEO. "Dr. Winkler brings vast clinical experience in Functional Medicine, a way of looking at the root cause of a person's disease and viewing each person as a unique individual to give his patients the best possible outcome in their care. Today we welcome Dr. Winkler aboard our distinguished Scientific Team," added Mr. Dixon.

"The Team at Therapeutic Solutions International represents a highly synergistic group comprised of internationally renowned oncologists, immunologists, and business people dedicated to finding solutions for cancer in an unbiased and open-minded manner" said Dr. Winkler, adding "Having interacted with various Team members for over 2 years, I am highly enthusiastic about contributing to this deeply motivated group in their efforts to solve the problem of cancer."

"The Functional Medicine perspective that Dr. Winkler brings to our group provides a fresh and highly innovative take on the oncological problems we deal with. Treatments such as intravenous vitamin C, which Dr. Winkler has been practicing for over a decade, and are only now being understood at a molecular level1. We hope to leverage Dr. Winkler's experiences and insights in order to develop novel and non-toxic cancer immunotherapies." said Dr. James Veltmeyer, Chief Medical Officer of the Company.

About Therapeutic Solutions International, Inc.
Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases. Immune modulation refers to the ability to upregulate (make more active) or downregulate (make less active) one's immune system. The Company's corporate website is

1 Lv et al. Vitamin C preferentially kills cancer stem cells in hepatocellular carcinoma via SVCT-2.

NPJ Precis Oncol. 2018 Jan 8;2(1):1

NEWS : 7/2/18

Therapeutic Solutions International Announces Clinical Proof of Concept of Nanoparticle Pterostilbene Formulation: NanoStilbene™

Early Clinical Trial Data Supports Enhanced Biodistribution of NanoStilbene™ Compared to Standard Pterostilbene When Orally Administered

Oceanside, CA -- July 02, 2018 -- InvestorsHub NewsWire -- Therapeutics Solutions International, Inc., (OTC Markets: TSOI) announced today pilot clinical data providing proof of concept that its NanoStilbene™ formulation of pterostilbene more effectively increases blood levels of the molecule as compared to conventional formulations. The clinical trial involves administration of NanoStilbene or comparator formulations of pterostilbene, to healthy volunteers, followed by a series of blood draws to determine the concentration of the compound.

"These early studies are critical to establishing the efficacy of our nanoparticle formulations to effectively deliver pterostilbene to the body," said Timothy Dixon, President, and CEO of Therapeutic Solutions International. "We are dedicated to developing First Class nutraceutical formulations that are science-driven. Through performing scientific validation at each step of the development process, we aim to fulfill this commitment to the Industry."

Pterostilbene is a naturally occurring analog of resveratrol, which has been published in the peer-reviewed literature to suppress the growth of various types of cancers1 including cervical cancer2, lung cancer3, triple negative breast cancer4, prostate cancer5, and glioma6.

"I am extremely pleased with the promising initial data we are receiving demonstrating efficacy of the NanoStilbene formulation to deliver enhanced concentrations of pterostilbene to the patient's blood stream." Said Dr. James Veltmeyer, Chief Medical Officer of the Company. "Given the ability of pterostilbene to enhance the efficacy of chemotherapeutic drugs7, as well as having activity as a monotherapy in animal models, we are hoping to expand the use of this highly interesting molecule."

1 Chen et al. Apoptotic and Nonapoptotic Activities of Pterostilbene against Cancer. Int. J. Mol. Sci. 2018, 19(1), 287;
2 Chatterjee et al. Resveratrol and Pterostilbene Exhibit Anticancer Properties Involving the Downregulation of HPV Oncoprotein E6 in Cervical Cancer Cells. Nutrients. 2018 Feb 21;10(2)
3 Ma et al. Pterostilbene exerts anticancer activity on non-small-cell lung cancer via activating endoplasmic reticulum stress. Sci Rep. 2017 Aug 14;7(1):8091.
4 Su et al. Pterostilbene inhibits triple-negative breast cancer metastasis via inducing microRNA-205 expression and negatively modulates epithelial-to-mesenchymal transition. J Nutr Biochem. 2015 Jun;26(6):675-85
5 Li et al. Pterostilbene acts through metastasis-associated protein 1 to inhibit tumor growth, progression and metastasis in prostate cancer. PLoS One. 2013;8(3):e57542.
6 Huynh et al. Pterostilbene suppressed irradiation-resistant glioma stem cells by modulating GRP78/miR-205 axis. J Nutr Biochem. 2015 May;26(5):466-75.
7 Schmidt et al. Case-specific potentiation of glioblastoma drugs by pterostilbene. Oncotarget. 2016 Nov 8;7(45):73200-73215.

NEWS : 6/25/18

Therapeutic Solutions International Releases "IsoStilbene" Injectable Formulation of Pterostilbene Under Granted Patent for Augmentation of Immunotherapy and Targeting of Cancer Stem Cells
IsoStilbene to be Included in Pan American Cancer Treatment Center Protocols

Oceanside, CA -- June 25, 2018 -- InvestorsHub NewsWire -- Therapeutics Solutions International, Inc., (OTC Markets: TSOI) announced today the formulation and initial clinical implementation of an injectable form of pterostilbene called "IsoStilbene derived from their '047 patent."

As previously announced TSOI has licensed its entire StemVacs Platform that includes our peptide pulsed dendritic cell vaccine (StemVacs), innaMune, MemoryMune, LymphoBoost, and NanoStilbene to Pan American Cancer Center ("Pan Am") in Tijuana Mexico.

"In adding IsoStilbene, an injectable formulation of pterostilbene, to Pan Am' arsenal of immuno-therapeutics, they now have the ability to provide booster dosing of pterostilbene to supplement the 10ml daily intake of NanoStilbene patients already receive as part of their overall treatment, by providing IsoStilbene intravenously," said Timothy Dixon, President and CEO of Therapeutic Solutions International. "This is now the fourth commercial product derived from the issued '047 patent and we are very excited to offer this to Pan Am as well," added Mr. Dixon.

Peer reviewed publications have demonstrated efficacy of the pterostilbene molecule at stimulating immunity to cancer, as well as targeting cancer stem cells1,2. Unfortunately, classical formulations of pterostilbene do not appear to deliver effective amounts of pterostilbene to cancer cells. For this reason, Therapeutic Solutions International has developed several alternative dosing formulations including the previously disclosed NanoStilbene, and now, IsoStilbene.

"Pterostilbene is a highly potent analogue of resveratrol, which has been shown by multiple investigators to possess therapeutic benefits in a variety of models of cancer. The current progress by the Company, combined with collaborators at the Pan Am Cancer Treatment Center, allows for rapid translation of these non-toxic cancer immunotherapeutic approaches to the clinic," said James Veltmeyer, MD, Chief Medical Officer of TSOI.

1 Huang et al. Modulation of macrophage polarization and lung cancer cell stemness by MUC1 and development of a related small-molecule inhibitor pterostilbene. Oncotarget. 2016 Jun 28;7(26):39363-39375.[]=8101&pubmed-linkout=1

2 Mak et al. Pterostilbene, a bioactive component of blueberries, suppresses the generation of breast cancer stem cells within tumor microenvironment and metastasis via modulating NF-B/microRNA 448 circuit. Mol Nutr Food Res. 2013 Jul;57(7):1123-34.

NEWS : 6/18/18

Therapeutic Solutions International Announces the Appointment of James Veltmeyer, MD as Chief Medical Officer

Oceanside, CA -- June 18, 2018 -- InvestorsHub NewsWire -- Therapeutics Solutions International, Inc., (OTC Markets: TSOI) previously announced their plans to provide access to its clinical stage cancer immunotherapy product StemVacs under the Right To Try law signed by President Trump on May 30th 2018, and have appointed Dr. James Veltmeyer as Chief Medical Officer of their future planned cancer clinic.

"Having Dr. Veltmeyer head up our future "Right To Try Cancer Clinic", as well as all other clinical programs underway is a dream come true for TSOI," said Timothy Dixon, President, and CEO of Therapeutic Solutions International. "In his role as Chief of the Department of Family Medicine at Sharp Grossmont Hospital, where he currently provides senior leadership to over 200 physicians, Dr. Veltmeyer has developed skills that few ever do, allowing him to bring a wealth of experience in management and medicine to bear on our programs. He is one of the most compassionate doctors I have ever known and he will be an amazing Chief Medical Officer to oversee our future clinic where we plan to treat the most critically ill among us, end-stage cancer patients," added Mr. Dixon.

"The future of medicine is unfolding right before our eyes at a very rapid pace. Cellular immunotherapies, such as the Company's StemVacs platform allow for reprogramming of the immune system to selectively attack the cancer stem cell, which is believed to be the root of tumor formation," said Dr. James Veltmeyer. "Having worked with the team at TSOI since joining their Scientific Advisory Board, I have been impressed at the Company's pragmatic approach towards hyper-accelerated therapeutics development. I look forward to my more involved role in leading clinical translation of the Company's discoveries from Bench to Bedside."

"There are very few people I know who can transition seamlessly from business to medicine, to basic research," said Thomas Ichim, Ph.D., Director of TSOI. "I have worked closely with Dr. Veltmeyer both at TSOI, and as well on his Congressional Campaign. Dr. Veltmeyer is a naturally born leader that cares #1 about patients. I look forward to working alongside Dr. Veltmeyer in transforming the future of medicine" added Dr. Ichim.

NEWS : 6/11/18

Therapeutic Solutions International Expands Adoptive Immunotherapy Portfolio by Incorporation of "Universal Cancer Antigen" into StemVacs Dendritic Cell Platform

OCEANSIDE, CA -- June 11, 2018 -- InvestorsHub NewsWire -- Therapeutics Solutions International, Inc., (OTC Markets: TSOI) announced today initiation of efforts to combine its existing CTCFL "universal cancer antigen", labeled as BRS-001, with its clinical stage StemVacs Dendritic Cell Platform.

The Company previously filed a patent on technologies covering novel means of stimulating the immune system to kill cancer using naturally made nanoparticles termed "exosomes"1. The patent whose Mexican rights are licensed to the Pan Am Cancer Treatment Centers, covers the production and composition of matter of agents aimed at immunologically eradicating cancer stem cells. In contrast to previous exosome-based cancer therapeutic approaches, the strategy disclosed in the patent involves focusing the immune system to attack the CTCFL protein, which is selectively found on cancer stem cells2.

"The CTCFL or BORIS protein represents a unique onco-target in the fight against cancer since it is only found on cancer cells and not healthy tissues. Our strategy possesses the possibility of inducing an immune response that would strike cancer at its very roots, the cancer stem cells" said Timothy Dixon, President and CEO of Therapeutic Solutions International.

"The recently approved Right to Try Law allows for accelerated clinical development of therapeutics that possess Phase I data. We plan to leverage this and other programs to take our scientific discoveries from the bench to the patient's bedside" said Dr. James Veltmeyer, Member of the Company's Scientific Advisory Board.

The BORIS Approach:

About Pan Am Cancer Treatment Center
Pan Am Cancer Treatment Center contact information:
Telephone: (619) 735-9581
Diego Rivera #2339 suite 108
Zona Rio, Tijuana B.C. 22010

(The Pan Am Cancer Treatment Center has 2 TSOI clinical trials now in Mexico. One is for breast cancer , and one is for prostate cancer)
Watch the Pan Am Cancer Treatment Center Video here :

NEWS : 6/6/18

Therapeutic Solutions International Announces Licensing of Additional Technologies to
Pan American Cancer Treatment Center

Pipeline DD : These are the 5 products have been licensed to the Pan Am Cancer Treatment Center :
(All of the 5 products are created using materials that do not require major regulatory efforts)

Cancer Metabolic DeTox: Derived from plants, apigenin is GRAS
MemoryMune: Cultured donor blood cells
StemVacs: Peptides
LymphoBoost: Repositioning of expired drug
innaMune: Cultured donor blood cells

Description of Products:

Patent Title: Targeting the Tumor Microenvironment through Nutraceutical Based Immunoadjuvants
Disclosed are compositions useful for the treatment of cancer which modulate tumor associated immunosuppression, thus acting as immunoadjuvants. In one embodiment a composition containing apigenin, is provided, said composition useful for inhibition of tumor associated immune suppression mediated through the molecule indolamine 2,3 deoxygenase (IDO). In another embodiment, liposomal apigenin is administered as a means of decreasing IDO expression.
Product Name: Cancer Metabolic DeTox:This is an orally administered agent that is derived from various herbs termed apigenin. The unique property of apigenin is that it inhibits a cancer associated metabolic pathway that degrades the amino acid tryptophan. Specifically, apigenin inhibits the enzyme indolamine 2,3 deoxygenase (IDO), which is responsible for breaking down tryptophan in the vicinity of the tumor and generating by-products such as kynurenine. It is known that immune activation is dependent on tryptophan being present in the tumor environment. The depletion of tryptophan and generation of kynurenine by tumor cells and tumor associated cells is a major cause of immune suppression in cancer. By administering Cancer Metabolic DeTox, the innate arm of the immune system has a chance to regenerate. This positions the patient for better outcome after administration of specific immune stimulating vaccines.

Patent Title: Methods of Re-Activating Dormant Memory Cells with Anticancer Activity
Disclosed are methods, protocols and compositions of matter useful for stimulation of anticancer immune responses. In one embodiment of the invention culture of buffy coat cells is performed in an environment resembling non-physiological conditions. Buffy coat derived products are subsequently harvested, concentrated, and added to a culture of monocytes and lymphocytes. Conditioned media from said second culture is subsequently utilized as an injectable solution for stimulation of anticancer immunity.
Product Name: MemoryMune:This is a product derived from a two-step culture process of donor blood cells. The product MemoryMune reawakens dormant immune memory cells. It is known that many cancer patients possess memory T cells that enter the tumor, however, once inside the tumor these cells are inactivated. MemoryMune contains a unique combination of growth factors specific for immune system cells called “cytokines”.

Patent Title: Stimulation of Immunity to Tumor Stem Cell Specific Proteins by Peptide Immunization
Treatment of cancer is disclosed through administration of proteins or specific peptides found on tumor stem cells in vivo, in a matter eliciting monocyte or dendritic cell migration in order to allow uptake of said administrated proteins or peptides, followed by administration of a maturation signal in vivo. The invention provides for treatment of cancer through induction of anticancer immunity and/or immunity towards tumor initiating stem cells.
Product Name: StemVacs:Cancer stem cells are the root of cancer. They are involved in maintaining tumor masses, causing metastasis, as well as initiating tumor relapse. In contrast to other cancer cells, cancer stem cells are extremely resistant to chemotherapy and radiation therapy. StemVacs is a subcutaneously administered vaccine comprised of immune stimulatory peptides resembling cancer stem cell specific proteins.

Patent Title:Augmentation of Anti-Tumor Immunity by Mifepristone and Analogues Thereof
The present invention relates to compositions of matter and methods useful for improving a treatment outcome and/or an alteration of immunity in a condition that benefits from immune stimulation. In particular, one embodiment of the invention teaches administration of sufficient doses of mifepristone or a derivative, alone, or in combination with an immunotherapeutic such as, but not limited to, an antibody, a vaccine, a cytokine, or a medicament whose therapeutic activity is associated with immune modulation.
Product Name: LymphoBoost: LymphoBoost is a proprietary formulation of Mifepristone, a drug approved for another indication, which we have shown to be capable of stimulating lymphocytes, particularly NK cells and T cells, both critical in maintaining anti-tumor immunity.

Patent Title: Activated Leukocyte Extract for Repair of Innate Immunity in Cancer Patients
Disclosed are compositions, methods of use, and pharmaceutical preparations useful for modulation of immune responses. In one embodiment a composition is extracted polyvalently activated peripheral blood mononuclear cells through dialysis. Said immune modulator is useful for treatment of cancer and alleviation of cancer associated immune depression. In one embodiment, said immunomodulator acts as a costimulatory of T cell activation by modulation of cytokine production. In one embodiment said immune modulator is concentrated for miRNA species capable of activating innate immune cells.
Product Name: innaMune: This is a biological product derived from tissue culture of blood cells derived from healthy donors. It is a combination of cytokines that maintain activity of innate immune system cells, as well as having ability to shift M2 macrophages to M1

NEWS : 5/31/18
Therapeutic Solutions International to Provide Patients Access to StemVacs Cancer Immunotherapy through Newly Passed Right to Try Law

NEWS : 5/21/18
Therapeutic Solutions International Releases "DermalStilbene" a Topical Formulation of Pterostilbene

NEWS : 5/15/18
Therapeutic Solutions International, Inc., to Initiate Clinical Trial of Patented Cancer Immunotherapy Adjuvant Nanostilbene

NEWS : 5/9/18
Therapeutic Solutions International, Inc., Announces the Appointment of Nassir Azimi, MD, to Science Board
Company to Iniate Investigational Cardiovascular Study with Dr. Azimi and Nanostilbene

NEWS : 5/1/18
Therapeutic Solutions International Launches Multi-Protocol Cancer Immunotherapy Clinical Trial with Pan Am Cancer Treatment
Company Aims to Leverage Transfer Factor Pulsed Autologous Dendritic Cells on StemVacs Platform with
Patented Augmenter of Cancer Immunotherapy NanoStilbene

Link to Pan Am Cancer Treatment Centers website :

Link to TSOI Patent covering NanoStilbene :

StemVacs is also the subject of a filed Investigational New Drug Application (IND #17448) with the U.S. FDA. The IND seeks to establish safety and immune response of cancer, targeting a new personalized dendritic cell vaccine.
StemVacs Website :

Link to TSOI StemVacs PR :

Link to BORIS/StemVacs patent application :

TSOI Patent Portfolio :

TSOI Management :

Timothy G. Dixon – President, CEO, & Chairman

Mr. Dixon currently serves as Chief Executive Officer, President, and Chairman of Therapeutic Solutions International, Inc. Mr. Dixon also serves as President and Chairman of OmniBiome, Inc., and President. Mr. Dixon previously served as the President of TMD Courses, Inc. from 2006 to 2012 and; as the President of Splint Decisions Inc. from 2010 to 2011. Mr. Dixon has attended hundreds of hours of continuing medical/dental education throughout the years and has produced many educational DVD’s used by dental professionals worldwide on the subject of parafunctional control, migraine prevention, therapeutic Botox injections, migraine pathophysiology, dental sleep medicine, and other therapeutic protocols. Mr. Dixon also has extensive experience in dealing with corporate compliance matters with the U.S. Food and Drug Administration, (FDA) as well as many international regulatory bodies.

Gerry B. Berg – Vice President, CFO, Director

Gerry B. Berg has served as our Vice-President and Chief Financial Officer since April 20, 2011.  Mr. Berg became a director of the Company on August 24, 2012.  Mr. Berg has over 30 years of senior management experience working with private and public companies.  From May 2010 to March 2011, Mr. Berg served as President and Chairman of the Board of Directors of Friendly Auto Dealers, Inc. and also served in a consulting capacity from March 2009 to May 2010.

Mr. Berg holds a Bachelors of Science in Accounting from Walsh College where he graduated Cum Laude.  Mr. Berg became a Certified Public Accountant in the State of Michigan in 1979 and in the State of California in 1984.  Mr. Berg does not currently practice as a Certified Public Accountant.

Thomas E.Ichim, Ph.D. – Director

Dr. Ichim was appointed to the Board of Directors on January 22, 2016.  Dr. Ichim is a seasoned biotechnology entrepreneur with a track record of scientific excellence. He has founded/co-founded several companies including Batu Biologics, Inc., Medvax Pharma Corp, ToleroTech Inc, bioRASI, and OncoMune LLC. To date, he has published 99 peer-reviewed articles and is co-editor of the textbooks “RNA Interference: From Bench to Clinical Translation” and “Immuno-Oncology Text Book.”

Dr. Ichim is an ad-hoc editor and sits on several editorial boards. Dr. Ichim is an inventor on over 50 patents and patent applications. Dr. Ichim has extensive experience with stem cell therapy and cellular product development through FDA regulatory pathways. Dr. Ichim spent over 7 years as the President and Chief Scientific Officer of Medistem, developing and commercializing a novel stem cell, the Endometrial Regenerative Cell, through drug discovery, optimization, preclinical testing, IND filing, and up through Phase II clinical trials with the FDA. Dr. Ichim has extensive experience in product development, regulatory filings, and business development.

Dr. Ichim has a BSc in Biology from the University of Waterloo, Waterloo, Ontario, Canada, an MSc in Microbiology and Immunology a University of Western Ontario, London, Ontario, Canada and a Ph.D. in Immunology from the University of Sciences Arts and Technology, Olveston Monserrat.

James Veltmeyer, MD – Chief Medical Officer

Dr. Veltmeyer is a board-certified family physician in La Mesa, California. A graduate of UC San Diego and the Ross University School of Medicine, he completed his residency through the UC San Francisco system where he became Chief of Family Medicine Residency, overseeing 36 doctors.

Dr. Veltmeyer, a member of the San Diego Critical Care Medical Group, has been elected for four years (2012, 2014, 2016, and 2017) by his colleagues in the San Diego County Medical Society as a “Physician of Exceptional Excellence,” the most prestigious honor awarded to a “Top Doctor” in San Diego County. He is among a select group of San Diego physicians who was chosen four of the last fifteen years and he consistently ranks in the top 1% to 2% for patient satisfaction. He is currently the Chief of the Department of Family Medicine at Sharp Grossmont Hospital where he provides senior leadership to over 200 doctors.

Hong Ma, MD, Ph.D., M.B.A. – Chief Scientific Officer

Dr. Ma has an extensive history in academic and translational research. Subsequent to completing her medical degree, she performed basic research in the area of molecular biology of endothelial-associated pathways in her doctorate and postdoctoral studies. She has been critical in establishing numerous ventures and collaborations in the area of biosciences. Dr. Ma has over 20 peer-reviewed publications and has worked with prestigious institutions in the USA, China, and Japan. She received her M.D. from Dalian Medical University, her Ph.D in Cardiovascular Pharmacology at Asahikawa Medical College, and has also earned her MBA at the Rady School of Management at the University of California San Diego.

TSOI Scientific Advisory Board :

TSI Facebook page :

Corporate website :

Nutraceutical Division :
E-Commerce site:

 Projuvenol®  is a Patented  proprietary mixture containing pterostilbene – one of the most potent antioxidants known.
 Additional Info :
NanoStilbene 150ml

NanoStilbene  is a form of pterostilbene containing nanoparticles, and is covered for use in cancer immunotherapy under the Company’s issued U.S. Patent.
DermalStilbene 60ml
DermalStilbene  is a topical form of pterostilbene . DermalStilbene is manufactured and sold under US Patent No.: 9,682,047.
   Image may contain: drink

IsoStilbene  is an injectable formulation of pterostilbene under granted patent, for Augmentation of Immunotherapy and Targeting of Cancer Stem Cells .

Share Structure :
AS - 1.5 B common , 5 M preferred -
IO - 882,908,307
Float - 70,343,547
SEC Filings :

Contact :

E - mail :
Address :
4093 Oceanside Blvd.
Suite B
Oceanside , CA
Phone :
(760) 295 - 7208

Disclaimer : All of the information presented in the IBOX , Stickies , or posts on this board , is based on individual opinions , and is not to be considered as a recommendation to buy , sell , or hold this stock.


Cannabis Report
Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
TSOI News: Therapeutic Solutions International, Inc., Appoints Juergen Winkler, MD, ABIHM to Scientific Advisory Board 07/09/2018 09:00:00 AM
TSOI News: Therapeutic Solutions International Announces Clinical Proof of Concept of Nanoparticle Pterostilbene Formulation: NanoStilbe... 07/02/2018 09:00:00 AM
TSOI News: Therapeutic Solutions International Releases "IsoStilbene" Injectable Formulation of Pterostilbene Under Granted Patent 06/25/2018 09:00:00 AM
TSOI News: Therapeutic Solutions International Announces the Appointment of James Veltmeyer, MD as Chief Medical Officer 06/18/2018 09:00:00 AM
TSOI News: Therapeutic Solutions International Expands Adoptive Immunotherapy Portfolio by Incorporation of "Universal Cancer Antigen" ... 06/11/2018 09:00:00 AM
PlusOneCoin Top Posts
No plusone'd posts yet. Be the first!
#7651  Sticky Note Bullet points DD centsability4me 07/15/18 02:20:47 PM
#6623  Sticky Note $TSOI up 25% setting up for a BLUE RobbinGood 06/08/18 02:30:17 PM
#7652   Hoping for a good week for TSOI... Abbas14 07/15/18 11:17:51 PM
#7651   Bullet points DD centsability4me 07/15/18 02:20:47 PM
#7649   those centsability4me 07/15/18 07:15:57 AM
#7648   Darn good question ... sharkey12 07/15/18 05:37:39 AM
#7647   TSOI)$$$... what is fair value of Tsoi stock Abbas14 07/15/18 01:51:15 AM
#7646   Bullet points DD centsability4me 07/14/18 06:25:50 AM
#7645   TSOI !! DAMN RIGHT I GOT MORE TODAY !! WEEDWACKO 07/13/18 05:25:29 PM
#7644   according the the I_HUB level 2 service I subslover 07/13/18 01:42:56 PM
#7643   TSOI $$ .. getting some buying volume and Abbas14 07/13/18 01:40:09 PM
#7642   Exactly MMatthews !!!! That is why us penny subslover 07/13/18 01:35:55 PM
#7641   Gotta have Iron clad balls to be in subslover 07/13/18 01:29:41 PM
#7640   Agree and sorry about the missed gains. Hindsight JMMatthews 07/13/18 01:29:34 PM
#7639   From what I can read in the analytics subslover 07/13/18 01:25:33 PM
#7638   Will be exciting when it does and people JMMatthews 07/13/18 01:17:22 PM
#7637   TSOI is a great Company,an undiscovered gem in subslover 07/13/18 01:06:26 PM
#7636   Very few shares left in the 01's and subslover 07/13/18 01:02:53 PM
#7635   TSOI $$.. I hope people stop selling... I Abbas14 07/13/18 01:01:17 PM
#7634   It looks fine imho,Today summer Friday and rumor subslover 07/13/18 12:54:33 PM
#7633   CEL* $$$ will make its way here eventually JMMatthews 07/13/18 12:43:22 PM
#7632   TSOI $$... where is all the buyers?? Not Abbas14 07/13/18 12:02:49 PM
#7631   Bullet points DD centsability4me 07/13/18 08:51:49 AM
#7630   decent size bid this am. sharkey12 07/13/18 07:14:05 AM
#7629   Pistol in the house keeping his eyes here sharkey12 07/13/18 06:29:43 AM
#7628   Thank you $Pistol Pete$ subslover 07/13/18 03:49:43 AM
#7627   $TSOI Daily and Weekly Charts http://www.stock $Pistol Pete$ 07/13/18 03:03:51 AM
#7626   Wow went under .01 JackAskSlap 07/12/18 09:15:04 PM
#7625   TSOI my shares are locked and thanks for Hugebuckslayer 07/12/18 08:47:49 PM
#7623   TSOI Who ever sold out at a loss X-ray07 07/12/18 03:15:24 PM
#7622   Great! Thank you! subslover 07/12/18 03:05:00 PM
#7621   TSOI !! MY BUDDY IS COMING IN WATCH WEEDWACKO 07/12/18 03:03:35 PM
#7620   TSOI !! LOCK-EM-UP - FOLKS !! WEEDWACKO 07/12/18 03:00:54 PM
#7619   TSOI !! NOW THATS HOW YOU GET SOME WEEDWACKO 07/12/18 02:59:13 PM
#7618   Stop the madness people !!!!! this is sharkey12 07/12/18 02:56:15 PM
#7617   TSOI !! LET ME GET SOME MORE HANG-ON !! WEEDWACKO 07/12/18 02:56:00 PM
#7616   TSOI !! NICE TY !! WEEDWACKO 07/12/18 02:55:28 PM
#7615   TSOI !! GOT THE BID SELL !! WEEDWACKO 07/12/18 02:54:48 PM
#7614   going to go bid ... sharkey12 07/12/18 02:53:04 PM
#7613   TSOI !! WHAT NEED SOME HELP !! Hang-on .. WEEDWACKO 07/12/18 02:50:46 PM
#7612   never fails centsability4me 07/12/18 02:39:27 PM
#7611   dirty game on TSOI... corvatsch 07/12/18 02:39:09 PM
#7610   loading more cheapies centsability4me 07/12/18 01:53:00 PM
#7609   Exactly! MM's know this as well and they subslover 07/12/18 01:52:14 PM
#7608   There you go!!! I would LOVE to sharkey12 07/12/18 01:50:34 PM
#7607   $TSOI brought down on low volume, holding for Dvdslave2006 07/12/18 01:46:32 PM
#7606   these low floaters go centsability4me 07/12/18 01:45:56 PM
#7605   I got too confident on this one ... sharkey12 07/12/18 01:41:24 PM
#7604   paying attn. centsability4me 07/12/18 01:40:33 PM
#7603   fingers crossed ... I have just seen a sharkey12 07/12/18 01:36:29 PM
#7602   Believe me .. holding mine 5 mil.... not Abbas14 07/12/18 01:33:49 PM